Good News Network · 19 hours ago

Groundbreaking Bowel Cancer Trial Had Zero Relapses for Patients After 33 Months

A small shift in timing and treatment -- immunotherapy before surgery rather than chemotherapy after -- has left 32 bowel cancer patients with zero recurrences after nearly three years, defying the odds in a disease where roughly a quarter of patients typically relapse. The NEOPRISM-CRC trial gave patients a short course of pembrolizumab ahead of their operations, and now researchers can track the treatment's success through personalized blood tests that detect lingering tumor DNA. "Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging," says Dr. Kai-Keen Shiu, who notes the approach may allow doctors to tailor therapy based on who needs more or less intervention. For 73-year-old Christopher Burston, life has returned to normal: "I feel very lucky that I've reached the stage where my main problem is age rather than cancer or any illness." What began as a carefully watched experiment has become a window into how precisely timed medicine might rewrite the future of cancer care.